在帕金森氏症模型中,乙化物通过抑制微质α-synuclein/TLR2/NF-κB/NLRP3轴来进行神经保护
Xue-Ping Yang1, Jia-Hua Huang2, Fan-Long Ye2
1Department of Integrated Traditional Chinese and Western Medicine, Institute of Integrative Medicine, Xiangya Hospital, Central South University, Changsha 410000, PR China; Laboratory of Neuropathology and Neuropharmacology, Department of Neurology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China; Institute of Neurology, Institutes of Integrative Medicine, Fudan University, Shanghai 201500, China.
概括
Echinacoside (ECH) 通过抑制α-synuclein和NLRP3炎症酶通路来预防帕金森病 (PD). 这种天然化合物通过向神经炎症为PD提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 乙化 (ECH) 在帕金森病 (PD) 中显示出神经保护潜力.
- 在PD中ECH作用的精确分子机制尚未完全理解.
- 神经炎症,特别是涉及NLRP3炎症酶,与PD病变发生有关.
研究的目的:
- 研究ECH在帕金森病模型中的神经保护作用.
- 阐明ECH调节神经炎症的分子机制.
- 探索ECH对PDNLRP3炎症酶通路的影响.
主要方法:
- 已建立的亚急性PD小鼠模型使用MPTP (1-甲基-4--1,2,3,6-四胺).
- 使用BV2微质细胞与α-synuclein (α-syn) 和MPP+ (1-methyl-4-phenylpyridinium) 进行治疗,以在体外建模PD.
- 采用了分子对接,免疫光,西部涂抹和小分子抑制剂来分析ECH的作用机制.
主要成果:
- 在体内,MPTP诱导了NLRP3炎症酶激活;在没有α-synuclein原始化的情况下,单独的MPP+无法在体内激活它.
- 对TLR2/NF-κB/NLRP3轴的外源性α-synuclein主导的微质激活,促进MPP+诱导的NLRP3炎症酶激活.
- 在MPTP治疗的小鼠和BV2细胞中,ECH显著抑制了α-synuclein上调.
- 通过ECH抑制了由α-synuclein触发的TLR2/NF-κB/NLRP3轴激活.
结论:
- 在PD模型中,ECH具有神经保护作用.
- 通过降低TLR2/NF-κB/NLRP3炎症轴的调节,ECH的功能.
- 通过减少α-synuclein表达来实现这一目标,从而减轻PD中的神经炎症.
相关概念视频
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Parkinson's Disease: Treatment
278
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
278


